Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.52 |
| ▸ | CDK4 | P11802 | 4/20 | 0.52 |
| ▸ | CCND1 | P24385 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29942246 | 0.88 | CDK4 (0.61) | HTR6CDK4CCND1KMT2AMTNR1A | |
| SCHEMBL20532528 | 0.88 | CDK4 (0.61) | HTR6CDK4CCND1KMT2AMTNR1A | |
| SCHEMBL9635379 | 0.86 | CDK4 (0.56) | HTR6CDK4CCND1MTNR1AMTNR1B | |
| SCHEMBL14064208 | 0.84 | CDK4 (0.57) | HTR6CDK4CCND1KMT2AMTNR1A | |
| SCHEMBL22439496 | 0.83 | HTR6 (0.59) | HTR6CDK4CCND1KMT2AMTNR1A | |
| Hydrochloric Acid SCHEMBL28092919 | 0.82 | HTR6 (0.43) | HTR6KMT2AMTNR1AMTNR1B | |
| SCHEMBL8143084 | 0.81 | HTR6 (0.51) | HTR6CDK4CCND1KMT2AMTNR1A | |
| SCHEMBL17063357 | 0.80 | HTR2A (0.47) | HTR6HTR2AHTR2CSLC6A4 | |
| SCHEMBL30641145 | 0.80 | HTR6 (0.52) | HTR6CDK4CCND1KMT2AMTNR1A | |
| SCHEMBL19551431 | 0.80 | HTR6 (0.52) | HTR6CDK4CCND1KMT2AMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2742047-B1 | ANTIBACTERIAL PIPERIDINYL SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2021-05-12 | — | — | EP | disclosed |
| US-9598407-B2 | Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones | JANSSEN SCIENCES IRELAND UC (IE) | 2017-03-21 | — | — | US | disclosed |
| CN-105503869-A | Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones | JANSSEN R & D IRELAND | 2016-04-20 | — | — | CN | disclosed |
| CN-103917540-B | Antibacterial piperidinyl-substituted 3, 4-dihydro-1H- [1, 8] naphthyridinones | JANSSEN R&D IRELAND (IE) | 2016-03-16 | — | — | CN | disclosed |
| US-20150158866-A1 | Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones | JANSSEN SCIENCES IRELAND UC (IE) | 2015-06-11 | — | — | US | disclosed |
| US-9012634-B2 | Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones | JANSSEN R&D IRELAND (IE) | 2015-04-21 | — | — | US | disclosed |
| CN-103917540-A | Antibacterial piperidinyl-substituted 3, 4-dihydro-1H- [1,8] naphthyridinones | JANSSEN R & D IRELAND | 2014-07-09 | — | — | CN | disclosed |
| EP-2742047-A1 | ANTIBACTERIAL PIPERIDINYL SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES | Janssen R&D Ireland (IE) | 2014-06-18 | — | — | EP | disclosed |
| US-20140163038-A1 | Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones | JANSSEN SCIENCES IRELAND UC (IE) | 2014-06-12 | — | — | US | disclosed |
| WO-2013021052-A1 | ANTIBACTERIAL PIPERIDINYL SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES | JANSSEN R&D IRELAND (IE) | 2013-02-14 | — | — | WO | disclosed |
| US-7348324-B2 | Cyclic amine compounds as CCR5 antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-03-25 | — | — | US | disclosed |
| EP-1886994-A1 | Cyclic amine compounds as CCR5 antagonists | Takeda Pharmaceutical Company Limited (JP) | 2008-02-13 | — | — | EP | disclosed |
| US-20030114443-A1 | Cyclic amine compounds as CCR5 antagonists | TOBIRA THERAPEUTICS, INC. | 2003-06-19 | — | — | US | disclosed |
| US-6562978-B1 | N-(3-(4-(4-(Aminocarbonyl)benzyl)-1-piperidinyl)propyl)-N-(3, 4-dichlorophenyl)-1-(methylsulfonyl)-4-piperidinecarboxamide or a salt thereof for treatment of AIDS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-05-13 | — | — | US | disclosed |
| CN-1390201-A | cyclic amine compounds as CCR5 antagonists | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-01-08 | — | — | CN | disclosed |
| EP-1220842-A1 | CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2002-07-10 | — | — | EP | disclosed |
| WO-2001025200-A1 | CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163038-A1 | Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones | FAR1, DNASE1, LAMP1 | HTR6 4784/4885CDK4 2199/4885CCND1 1708/4885 |
| US-20030114443-A1 | Cyclic amine compounds as CCR5 antagonists | CCR5, CCR1, CCR3 | HTR6 566/4885CDK4 4226/4885CCND1 1615/4885 |
| US-20150158866-A1 | Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones | NQO2, ALPI, ECI1 | HTR6 4733/4885CDK4 1953/4885CCND1 2032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.